Fluoroescaline

Fluoroescaline
Clinical data
Other namesFE; 2-Fluoroescaline; 2-FE; FEM; 4-(2-Fluoroethoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(2-fluoroethoxy)phenethylamine
Routes of
administration		Oral[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action~6 hours[1][2][3]
Identifiers
  • 2-[4-(2-fluoroethoxy)-3,5-dimethoxyphenyl]ethanamine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H18FNO3
Molar mass243.278 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OCCF)OC)CCN
  • InChI=1S/C12H18FNO3/c1-15-10-7-9(3-5-14)8-11(16-2)12(10)17-6-4-13/h7-8H,3-6,14H2,1-2H3
  • Key:RODJFRFKJSPAGG-UHFFFAOYSA-N

Fluoroescaline (FE), also known as 4-(2-fluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a fluorinated derivative of escaline.[1][2][3] The drug is active at a dose of 75 mg or more orally and its duration is approximately 6 hours.[1][2][3] The drug has not been fully tested and it produced only weak hallucinogenic effects and no closed-eye or open-eye visuals at dose of 75 mg.[1] Fluoroescaline is notably less potent than escaline.[1][2][3] It is a low-potency near-full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[3] The chemical synthesis of fluoroescaline has been described. Fluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002.[1][2][3][4] Its pharmacology was subsequently described in further detail in 2021.[3]

See also

References

  1. ^ a b c d e f g h Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 706, 710–711, 716–717, 736–737. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. ^ a b c d e f g Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  3. ^ a b c d e f g h i Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  4. ^ Trachsel D (2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate". Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.